慢性阻塞性肺疾病患者血浆脑钠肽增高的机制

doi:10.3969/j.issn.1006-7795.2016.05.005

摘要/Abstract

摘要： 慢性阻塞性肺疾病是一种炎性反应性疾病，这种炎性反应可累及心血管系统，导致慢性阻塞性肺疾病患者心血管疾病的发生率增加，心脏标志物脑钠肽及其前体与慢性阻塞性肺疾病的相关研究成为热点。本文就慢性阻塞性肺疾病患者血浆脑钠肽增高的机制予以综述。

关键词: 慢性阻塞性肺疾病, 脑钠肽, 肺过度充气, 炎性反应

Abstract: Chronic obstructive pulmonary disease (COPD) is an inflammatory disease which can affect the cardiovascular system resulting in an increased incidence of cardiovascular disease in COPD. The relationship between the cardiac markers such as brain type natriuretic peptide (BNP) and its precursor and COPD becomes a hot topic. This article reviews the mechanism of the increased level of plasma BNP in patients with COPD.

Key words: chronic obstructive pulmonary disease, brain type natriuretic peptide, hyperinflation, inflammation

中图分类号:

R563

苗苗, 卜小宁. 慢性阻塞性肺疾病患者血浆脑钠肽增高的机制[J]. 首都医科大学学报, 2016, 37(5): 583-587.

Miao miao, Bu Xiaoning. Mechanism of the increased level of plasma brain type natriuretic peptide in chronic obstructive pulmonary disease[J]. Journal of Capital Medical University, 2016, 37(5): 583-587.

参考文献

[1] Vestbo J, Hurd S S, Agusti A G, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease:gold executive summary[J]. Am J Respir Crit Care Med, 2013,187(4):347-365.
[2] Cavailles A, Brinchault-Rabin G, Dixmier A, et al. Comorbidities of copd[J]. Eur Respir Rev, 2013,22(130):454-475.
[3] Lee M H, Chang C L, Davies A R, et al. Cardiac dysfunction and n-terminal pro-b-type natriuretic peptide in exacerbations of chronic obstructive pulmonary disease[J]. Intern Med J, 2013,43(5):595-598.
[4] Inoue Y, Kawayama T, Iwanaga T, et al. High plasma brain natriuretic peptide levels in stable copd without pulmonary hypertension or cor pulmonale[J]. Internal Med,2009,48(7):503-512.
[5] Medina A M, Marteles M S, Saiz E B, et al. Prognostic utility of nt-probnp in acute exacerbations of chronic pulmonary diseases[J]. Eur J Intern Med, 2011, 22(2):167-171.
[6] Pirracchio R, Deye N, Lukaszewicz AC, et al. Impaired plasma b-type natriuretic peptide clearance in human septic shock[J]. Crit Care Med, 2008,36(9):2542-2546.
[7] Fabbri L M, Rabe K F. From copd to chronic systemic inflammatory syndrome[J]. The Lancet,2007,370(9589):797-799.
[8] 蔡柏蔷.应重视慢性阻塞性肺疾病的合并症问题[J].中华结核和呼吸杂志,2013,36(4):245-247.
[9] Mascarenhas J, Azevedo A, Bettencourt P. Coexisting chronic obstructive pulmonary disease and heart failure:Implications for treatment, course and mortality[J]. Curr Opin Pulm Med, 2010,16(2):106-111.
[10] Gariani K, Delabays A, Perneger TV, et al. Use of brain natriuretic peptide to detect previously unknown left ventricular dysfunction in patients with acute exacerbation of chronic obstructive pulmonary disease[J]. Swiss Med Wkly, 2011,141:w13298.
[11] Curkendall S M, DeLuise C, Jones J K, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, saskatchewan canada cardiovascular disease in copd patients[J]. Ann Epidemiol,2006,16(1):63-70.
[12] Hoiseth AD, Omland T, Hagve TA, et al. NT-proBNP independently predicts long term mortality after acute exacerbation of copd-a prospective cohort study[J]. Respir Res, 2012,13:97.
[13] Zhang J, Zhao G, Yu X, et al. Intravenous diuretic and vasodilator therapy reduce plasma brain natriuretic peptide levels in acute exacerbation of chronic obstructive pulmonary disease[J]. Respirology,2012,17(4):715-720.
[14] 王秋月,张明娜. 不容忽视的慢性阻塞性肺疾病合并肺动脉高压[J].中华结核和呼吸杂志,2013,36(4):250-252.
[15] Weitzenblum E, Chaouat A, Kessler R. Pulmonary hypertension in chronic obstructive pulmonary disease[J]. Pneumonologia i alergologia polska,2013,81:390-398.
[16] Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in copd[J]. Pneum-onol Alergol Pol, 2008, 32(4):1371-1385.
[17] Leuchte H H, Neurohr C, Baumgartner R, et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension[J]. Am J Respir Crit Care Med,2004,170(4):360-365.
[18] Kanat F, Vatansev H, Teke T. Diuretics, plasma brain natriuretic peptide and chronic obstructive pulmonary disease[J]. Neth J Med, 2007,65(8):296-300.
[19] Gemici G, Erdim R, Celiker A, et al. B-type natriuretic peptide levels in patients with copd and normal right ventricular function[J]. Adv Ther, 2008,25(7):674-680.
[20] Nishimura K, Nishimura T, Onishi K, et al. Changes in plasma levels of b-type natriuretic peptide with acute exacerbations of chronic obstructive pulmonary disease[J]. Int J Chron Obstruct Pulmon Dis,2014,9:155-162.
[21] Van Gestel Y R, Goei D, Hoeks S E, et al. Predictive value of nt-probnp in vascular surgery patients with copd and normal left ventricular systolic function[J]. COPD, 2010,7(1):70-75.
[22] Watz H, Waschki B, Meyer T, et al. Decreasing cardiac chamber sizes and associated heart dysfunction in COPD:role of hyperinflation[J]. Chest,2010,138(1):32-38.
[23] Vassaux C, Torre-Bouscoulet L, Zeineldine S, et al. Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPD[J]. Eur Respir J, 2008,32(5):1275-1282.
[24] Barr R G, Bluemke D A, Ahmed F S, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling[J]. N Engl J Med,2010, 362(3):217-227.
[25] Chua G, Kang-Hoe L. Marked elevations in n-terminal brain natriuretic peptide levels in septic shock[J]. Crit Care, 2004,8(4):248-250.
[26] Nikolaou N I, Goritsas C, Dede M, et al. Brain natriuretic peptide increases in septic patients without severe sepsis or shock[J]. Eur J Intern Med,2007, 18(7):535-541.
[27] Burjonroppa S C, Tong A T, Xiao L C, et al. Cancer patients with markedly elevated b-type natriuretic peptide may not have volume overload[J]. Am J Clin Oncol, 2007, 30(3):287-293.
[28] Maeder M, Ammann P, Kiowski W, et al. B-type natriuretic peptide in patients with sepsis and preserved left ventricular ejection fraction[J]. Eur J Heart Fail, 2005,7(7):1164-1167.
[29] Solus J, Chung C P, Oeser A, et al. Stein CM:Amino-terminal fragment of the prohormone brain-type natriuretic peptide in rheumatoid arthritis[J]. Arthritis Rheum, 2008, 58(9):2662-2669.
[30] George J, Mackle G, Manoharan A, et al. High bnp levels in rheumatoid arthritis are related to inflammation but not to left ventricular abnormalities:A prospective case-control study[J]. Int J Cardiol, 2014,172(1):e116-118.
[31] Meirovich Y F, Veinot J P, de Bold M L, et al. Relationship between natriuretic peptides and inflammation:Proteomic evidence obtained during acute cellular cardiac allograft rejection in humans[J]. J Heart Lung Transplant, 2008,27(1):31-37.
[32] Chang C L, Robinson S C, Mills G D, et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of copd[J]. Thorax,2011, 66(9):764-768.
[33] Maries L, Manitiu I. Diagnostic and prognostic values of b-type natriuretic peptides (bnp) and n-terminal fragment brain natriuretic peptides (nt-pro-bnp)[J]. Cardiovasc J Afr,2013,24(7):286-289.
[34] Horwich T B, Hamilton M A, Fonarow G C. B-type natriuretic peptide levels in obese patients with advanced heart failure[J]. J Am Coll Cardiol, 2006,47(1):85-90.
[35] Das S R, Drazner M H, Dries D L, et al. Impact of body mass and body composition on circulating levels of natriuretic peptides:results from the Dallas Heart Study[J]. Circulation,2005,112(14):2163-2168.
[36] van Kimmenade R, van Dielen F, Bakker J, et al. Is brain natriuretic peptide production decreased in obese subjects[J]. J Am Coll Cardiol, 2006, 47(4):886-887.
[37] 赵东利, 彭燕. 慢性阻塞性肺疾病并发支气管扩张49例临床分析[J]. 中国煤炭工业医学杂志,2014,17(12):1984-1986.
[38] 黄思代, 陈水琴. 慢性阻塞性肺疾病合并气胸19例误诊分析[J]. 临床误诊误治,2013,26(11):32-34.
[39] 宫海艳, 温海艳,姜莉. 慢性阻塞性肺疾病合并肺间质纤维化的临床分析[J]. 中国医科大学学报,2013,42(3):262-263.